FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank, has been informed that Mr Arnoud van Tulder, Chief Executive Officer, purchased 2,000 ordinary shares of Euro 0.10 ('Ordinary Shares') at a price of €5.03 on 24 May 2011.
Following this purchase, Arnoud van Tulder is beneficially interested in 17,000 ordinary shares, representing approximately 0.18% of the Group's issued share capital.
Cryo-Save, the leading international family stem cell bank, already stores 175,000 samples from cord blood and umbilical cord tissue for newborns and adipose tissue for adults. These stem cells can mean the difference between life and death in the case of future threats to the health of the donors. There are already several diseases that can be cured by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and France (validation in progress).
Source: Cryo-Save Group
Tags: stock market